Trial Profile
Phase II Study: Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib (TACTICS).
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Antineoplastics; Lenvatinib; Ramucirumab; Regorafenib
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms TACTICS
- 17 Jan 2021 Primary endpoint (Overall Survival) has not been met as per results presented at the 2021 Gastrointestinal Cancers Symposium
- 17 Jan 2021 Results of Final overall survival analysis presented at the 2021 Gastrointestinal Cancers Symposium
- 04 Dec 2019 Results assessing efficacy and safety of transarterial chemoembolisation (TACE) plus sorafenib in patients with hepatocellular carcinoma, published in the Gut.